Roche announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase
More From BioPortfolio on "Roche's Alecensa gets Chinese marketing nod to treat ALK─positive, advanced NSCLC"